Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin
|ClinicalTrials.gov Identifier: NCT01720940|
Recruitment Status : Unknown
Verified November 2012 by Medicine, National University Hospital, Singapore.
Recruitment status was: Recruiting
First Posted : November 2, 2012
Last Update Posted : November 2, 2012
This study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion.
This study will recruit 220 subjects from 2 hospitals over a period of 3 years.
Participants are invited if they have an infection that requires prolonged vancomycin therapy (> more than 10 days).
|Condition or disease||Intervention/treatment||Phase|
|Infections Requiring Prolonged Duration (>10 Days) of Vancomycin||Drug: continuous vancomycin infusion Drug: intermittent vancomycin infusion||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||220 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin|
|Study Start Date :||October 2012|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||September 2015|
|Experimental: continuous vancomycin infusion||
Drug: continuous vancomycin infusion
24-hour continuous infusion of vancomycin
Active Comparator: intermittent vancomycin infusion
vancomycin in this arm will be administered as intermittent infusion
Drug: intermittent vancomycin infusion
- nephrotoxicity [ Time Frame: occurring any time while on vancomycin treatment up to 14 days post treatment completion ]nephrotoxicity as defined by the acute kidney injury network (AKIN) criteria using only serum creatinine criteria
- biomarkers for detection of early nephrotoxicity [ Time Frame: measured weekly from the date of randomization until 14 days post completion of vancomycin ]serum and urine NGAL and cystatin C
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01720940
|Contact: Shire Yang Tanfirstname.lastname@example.org|
|National University Hospital||Recruiting|
|Contact: Shire Yang Tan 97989001 email@example.com|
|Principal Investigator: Dale Fisher|